Salvage Radiation Therapy Improves Metastasis-free Survival for Clinically Aggressive and Indolent Prostate Cancer Recurrences after Radical Prostatectomy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 4, 2015, Pages 367-372

  Jackson, William C ^a   Johnson, Skyler B ^a   Feng, Felix Y ^a   Hamstra, Daniel A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

gleason score; metastasis free survival; prostate cancer; PSA doubling time; salvage radiation therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS FREE SURVIVAL; MULTIMODALITY CANCER THERAPY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL RATE; AGED; BLOOD; CANCER GRADING; DISEASE FREE SURVIVAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

AGED; DISEASE-FREE SURVIVAL; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84938748863     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31829e17db     Document Type: Article

References (16)

1. Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012;109:32-39
2. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597
3. Sandler HM, Eisenberger MA. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol. 2007;178:S20-S24
4. Darwish OM, Raj GV. Management of biochemical recurrence after primary localized therapy for prostate cancer. Front Oncol. 2012;2:48
5. Raldow A, Hamstra DA, Kim S, et al. Salvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversy. Oncology (Williston Park). 2010; 24:692-700, 702
6. Cotter SE, Chen MH, Moul JW, et al. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011;117:3925-3932
7. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299:2760-2769
8. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540-545
9. Lawton CA, Winter K, Byhardt R, et al. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN +) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1997;38:931-939
10. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781-1788
11. Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis. 2004;7:211-216
12. Ornstein DK, Colberg JW, Virgo KS, et al. Evaluation and management of men whose radical prostatectomies failed: results of an international survey. Urology. 1998;52:1047-1054
13. Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007;51:1175-1184
14. Shilkrut M, Feng F, Hamstra DA. General commentary to the "management of biochemical recurrence after primary localized therapy for prostate cancer" by Darwish O.M. and Raj G.V. Front Oncol. 2012;2:126
15. Shipley DH WU, Lukka HR, Major P, et al. Sandler Initial report of RTOG 9601, a phase III trial in prostate cancer: effect of antiandrogen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3, N0 disease and elevated PSA levels. 2011 American Society of Clinical Oncology Genitourinary Cancers Symposium
16. Parker C, Clarke N, Logue J, et al. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin Oncol (R Coll Radiol). 2007;19:167-171